KR880012558A - 진통활성을 갖는 아릴헤테로아릴 카르비놀 유도체와 그의 제조방법 - Google Patents
진통활성을 갖는 아릴헤테로아릴 카르비놀 유도체와 그의 제조방법 Download PDFInfo
- Publication number
- KR880012558A KR880012558A KR1019880004094A KR880004094A KR880012558A KR 880012558 A KR880012558 A KR 880012558A KR 1019880004094 A KR1019880004094 A KR 1019880004094A KR 880004094 A KR880004094 A KR 880004094A KR 880012558 A KR880012558 A KR 880012558A
- Authority
- KR
- South Korea
- Prior art keywords
- methanol
- methyl
- imidazole
- chlorophenyl
- pyrazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- 다음의 일반식)(Ⅰ)로 표시되는 아릴헤테로아릴카르비놀 유도체와 그의 치료학적으로 허용 가능한 염.여기서,R1,R2및R3는 서로 동일하거나 다르며,수소원자나 할로겐,저급알킬 라디칼, 저급 알킬 라디칼, 저급 알콕시 라디칼 또는 트리플루오로메틸기를 나타내고,R4는 수소원자,C1내지 C3의 저급 알킬 라디칼, 사이클 로알킬, 저급 알케닐 라디칼 또는 질소원자가 치완된 사이클로알킬아미노를 나타내고, R5는 수소원자나,다음의 일반식으로 표시되는 라디칼을 나타내거나,(여기서,n은 1또는 2이며,R6과 R7은 서로 동일하거나 다르며, 저급 알킬이나 사이틀로알킬 또는 사이클로알콕시를 나타내는 바,은 저급 디알킬아미노이거나, 피페리디노,모르포리노 및 피롤리디노기중에서 선택된 환형아민라디칼을 나타낸다.)또는 다음의 일반식으로 표시되는 기를 나타내며,(여기서,n은 1또는 2이며,R8은 저급 알킬기를 나타낸다.)Het는 다음의 (a),(b),(c)중에서 선택된 아졸을 나타낸다.(a)다음의 일반식으로 표시되는 피라졸,(여기서,R9는 수소원자, C1내지 C4의 저급 알킬 라디칼, 도데실 라디칼 ,벤질 라디칼 또는n이 1또는 2인-(CH2)n-CH2-라디칼을 나타내며, R10은 메틸라디칼 또는 할로겐원자를 나타낸다.)(b)다음의 일반식 표시되는 아미다졸.(여기서, R11은 수소우너자, C1내지 C4의저급 알킬 라디칼, 벤질 라디칼, 도데실 라디칼 또는 n이 2,3또는 4이고 A가 피레리디노 라디칼, 시아노 라디칼, 하이드록실 하디칼, 카르복실 라디칼, 아미노기, 카르복시 메틸 라디칼 또는 메틸 에스테르기를 나타내는 A-(CH2)n-라디칼을 나타낸다.)(c)다음 구조식을 표시되는 아미다졸.
- 제1항에 있어서, 일반식(Ⅰ)로 표시되는 화합물은 다음에 나열한 화합물중에서 선택된 것임을 특징으로 하는 화합물.(1) 1-메틸-α-페닐-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,2)α-(4-클로로페닐)-α-메틸-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,3)α-(4-클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,4)α-(3-클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,5)α-(2-클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,6)α-(4-클로로페닐)-α-메틸-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,7)α-메틸-1-메틸-α-(3-트리플루오로메틸페닐)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,8)α-(3-클로로페닐)-α-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,9)α-부틸-α-(3-클로로페닐)-1-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,10)1-부틸-α-(3-클로로페닐)-α-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,11)α-(4-메톡시페닐)-α-메틸-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,12)α-(3-클로로페닐)-α-메틸-1-메틸-0-(에틸-2-N-피롤리딘)-1H-이미다졸-2-메탄올,13)α-부틸-1-도데실-α-(3,4,5-트리메톡시페닐)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,14)1-부틸-α-(4-트리플루오로메틸페닐)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,15)1-부틸-α-(3-틀리플루오로메틸페닐)-0-(에틸-2-N-피페리딘)-1H-이미다졸-2-메탄올,16)-α-사이클로헥실-α-(3,4-디클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,17)α-부틸-α-(3,4-디클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,18)α-(3-디클로로페닐)-α-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,19)α-(3-클로로페닐)-1-메틸-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,20)α-(4-클로로페닐)-1-(에틸-2-N-피페리딘)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,21)α-(4-클로로페닐)-α-메틸-1-(프로필-3-N-피페리딘)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,22)1-(3-시아노프로필)-α-(4-클로로페닐)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,23)1-(4-클로로페닐)-1-메틸-α-(N-메틸피페리딘-4-일)-0-(2-디메틸아미노에틸)-1H-이미다졸-2-메탄올,24)α-(4-클로로페닐)-1-벤질-0-(2-N-메틸-2-N-벤질아미노에틸)-1H-이미다졸-2-메탄올,25)α-(4-클로로페닐)-α-메틸-7-메틸-0-(2-디메틸아미노에틸)-6,7,8,9-타트라하이도로-1H-이미다졸[1,5-아] [1,4]디아제핀-2-메탄올,26)α-(4-클로로페닐)-7-메틸-0-(2-디메틸아미노에틸)-6,7,8,9-테트라하이드로-1H-이미다졸[1,5-아] [1,4] 디아제핀-2-메탄올,27)1-부틸-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,28)α-(4-클로로페닐)-1-메틸-α-페닐-0-(디메틸아미노에틸)-1H-피라졸-5-메탄올,29)1-부틸-α-(3,4,5-트리메톡시페닐-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,30)1-부틸-α-(4-클로로페닐)-α-메틸-0-82-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,31)1-메틸-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,32)α-메틸-1-메틸-0-(2디메틸아미노에틸)-1H-피라졸-5-메탄올,33)1-부틸-α-(3,4,5-트리메톡시페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,34)1-메틸-0-[에틸-2-(1-피롤리딘)-1H-피라졸-5-메탄올,35)1-메틸-0-(에틸-2-N-모르포린)-1H-피라졸-5-메탄올,36)α-메틸-1-메틸-α-(3,4,5-트리메톡시페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,37)4-브로모-1-메틸-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,38)1,3-디메틸-α-메틸-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,39)1,3-디메틸-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,40)1-메틸-α-(2-메틸페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,41)1-메틸-4-클로로-α-(4-클로로페닐)-0-(2-아미노에틸)-1H-피라졸-5-메탄올,42)1-메틸-α-(4-클로로페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,43)1-메틸-α-메틸-α-(4-클로로페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,44)1-메틸-α-(4-클로로페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,45)1-메틸-α-(3-클로로페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,46)1-메틸-α-(4-메틸페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,47)1-메틸-α-(2-클로로페닐)-0-(2-디메틸아미노에틸)-1H-피라졸-5-메탄올,48)1-메틸-α-페닐-0-(에틸-2-N-피페리딘)-1H-피라졸-5-메탄올,49)1-메틸-α-0-[2-(N-프로필피페리딘-2-일)에틸]-1H-피라졸-5-메탄올,50)1-메틸-α-(4-클로로페닐)-0-[2-(N-프로필피페리딘-2-일)에틸]-1H-피라졸-5-메탄올,51)1-메틸-α-0-[2-(N-프로필피페리딘-2-일)에틸]-1H-피라졸-5-메탄올,52)1-메틸-α-0-[2-(N-프로필피페리딘-2-일)에틸]-1H-피라졸-5-메탄올,53)1-메틸-α-0-(2-디이소프로필아미노에틸)-1H-피라졸-5-메탄올,54)1-메틸-α-(4-클로로페닐)-0-[2-(N-메틸피페리딘-2-일)에틸]-1H-피라졸-5-메탄올55)1-메틸-α-페닐-0-[2-(N-메틸피페리딘-2-일)에틸]-1H-피라졸-5-메탄올56)1-메틸-α-페닐-0-[2-(N-메틸피페리딘2-일)에틸]-1H-피라졸-5-메탄올57)1-메틸-α-(4-클로로페닐)-0-(2-디이소프로필아미노에틸)-1H-피라졸-5-메탄올,58)1-메틸-α-(4-클로로페닐)-0-[2-(N-메틸피롤리딘-2-일)에틸]-1H-피라졸-5-메탄올,59)α-(4-클로로페닐)-α-메틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,60)α-(3-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,61)α-(4-클로로페닐)-α-에틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,62)α-부틸-α-(3-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,63)α-(4-클로로펜닐)-α-사이클로헥실-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,64)α-(4-클로로페닐)-α-메틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,65)α-메틸-1-메틸-α-(3-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,66)α-(2-클로로페닐)-α-메틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,67)α-(3-클로로페닐)-α-메틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,68)α-메틸-1-메틸-α-(3,4,5-트리메톡시페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,69)α-메틸-1-메틸-α-(4-메톡시페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,70)α-(4-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,71)1-메틸-α-(3,4,5-트리메톡시페닐-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,72)α-메틸-1-메틸-α-(4-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,73)1-메틸-α-(3-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,74)1-메틸-α-(4-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,75)α-(4-메톡시페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,76)α-메틸-1-메틸-α-(3-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,77)1-부틸-α-(4-클로로페닐)-α-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,78)1-부틸-α-부틸-α-(3,4,5-트리메톡시페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,79)1-부틸-α-부틸-α-(2-클로로페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,80)1-부틸-α-(2,4-디클로로페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,81)1-부틸-α-(4-트리플루오로메틸페닐)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,82)α-(4-클로로페닐)-1-메틸-0-(프로필-3-N-피페리딘)-1H-이미다졸-5-메탄올,83)α-메틸-1-메틸-α-(4-트리플루오로메틸페닐)-0-(프로필-3-N-피페리딘)-1H-이미다졸-5-메탄올,84)α-부틸-α-(2-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,85)α-부틸-α-(3,4-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,86)α-(3,4-클로로페닐)-α-메틸-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,87)α-(3,4-클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,88)α-사이클로프로필-α-(3,4,-디클로로페닐)-1-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,89)α-(4-클로로페닐)-1-(에틸-2-N-피페리딘)-α-메틸-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,90)α-(4-클로로페닐)-α-메틸-1-(프로필-3-N-피페리딘)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,91)α-(4-클로로페닐)-1-메틸-α-(N-메틸피페리딘-4-일)-0-(3-디메틸아미노프로필)-1H-이미다졸-5-메탄올,92)1-부틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,93)1-부틸-α-(4-클로로페닐)-α-메틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,94)1-메틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,95)1-메틸-α-메틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,96)1,3-디메틸-α-메틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,97)1,3-디메틸-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,98)1-메틸-α-(2-메틸페닐)-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,99)1-메틸-α-(4-클로로페닐)-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,100)1-메틸-α-페닐-0-(3-디메틸아미노프로필)-1H-피라졸-5-메탄올,101)1-메틸-α-(4-클로로페닐)-0-(프로필-3-N-모르포린)-1H-피라졸-5-메탄올,102)1-메틸-α-(4-클로로페닐)-0-(프로필-3-N-피를리딘)-1H-피라졸-5-메탄올,103)1-메틸-α-페닐-0-(프로필-3-N-모르포린)-1H-피라졸-5-메탄올,104)1-메틸-α-페닐-0-(프로필-3-N-모르포린)-1H-피라졸-5-메탄올,105)α-페닐-1H-이미다졸-2-메탄올,106)α-(4-클로로페닐)1H-이미다졸-2-메탄올,107)α-(4-클로로페닐)1-메틸-1H-이미다졸-2-메탄올,108)α-(3-클로로페닐)-메틸-1H-이미다졸-2-메탄올,109)α-(4-플루오로페닐)-1-메틸-1H-이미다졸-2-메탄올,110)1-메틸-α-(3-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,111)1-메틸-α-(4-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,112)1-메틸-α-(3,4,5-트리메톡시페닐)-1H-이미다졸-2-메탄올,113)α-(3,4-디클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,114)1-부틸-α-(4-트리플루오레메틸페닐)-1H-이미다졸-2-메탄올,115)1-부틸-α-(2,4-디클로로페닐)-1H-이미다졸-2-메탄올,116)1-부틸-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,117)1-메틸-α-(3,4,5-트리메톡시페닐)-1H-이미다졸-2-메탄올,118)1-도데실-α-(3,4,5-트리메톡시페닐)-1H-이미다졸-2-메탄올,119)α-부틸-α-(3-클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,120)α-(3-클로로페닐)-α-메틸-1-1H-이미다졸-2-메탄올,121)α-(4-클로로페닐)-α-메틸-1-메틸-1H-이미다졸-2-메탄올,122)α-(4-클로로페닐)-α-(N)-메틸피페리딘-4-일)-1-메틸-1H-이미다졸-2-메탄올,123)α-(4-클로로페닐)-α-에틸-1-메틸-1H-이미다졸-2-메탄올,124)α-부틸-α-(4-클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,125)α-(4-클로로페닐)-α-사이클로헥실-1-메틸-1H-이미다졸-2-메탄올,126)α-(2-클로로페닐)-α-메틸-1-메틸-1H-이미다졸-2-메탄올,127)α-부틸-α-(2-클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,128)α-메틸-1-메틸-α-(3-트리플루오로메틸페닐)-1-이미다졸-2-메탄올,129)α-부틸-1-메틸-α-(3-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,130)α-사이클로헥실-1-메틸-α-(4-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,131)α-메틸-1-메틸-α-(4-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,132)α-(4-플루오로페닐)-α-메틸-1-메틸-1H-이미다졸-2-메탄올,133)α-(4-메톡시페닐)-α-메틸-1-메틸-1H-이미다졸-2-메탄올,134)α-(3,4-디클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,135)α-부틸-α-(3,4-디클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,136)α-사이클로헥실-α-(3,4-디클로로페닐)-1-메틸-1H-이미다졸-2-메탄올,137)α-메틸-1-메틸-α-(3,4,5-트리메톡시페닐)-1H-이미다졸-2-메탄올,138)1-부틸-α-(4-클로로페닐)-α-메틸-1H-이미다졸-2-메탄올,139)1-부틸-α-부틸-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,140)1-부틸-α-(4-클로로페닐)-α-(N-메틸피페리딘-4-일)-1H-이미다졸-2-메탄올,141)1-부틸-α-부틸-α-(3,4,5-트리메톡시페닐)-1H-이미다졸-2-메탄올,142)1-부틸-α-부틸-α-(2-클로로페닐)-1H-이미다졸-2-메탄올,143)1-부틸-α-에틸-α-(3-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,144)1-부틸-α-부틸-α-(2,4-디클로로페닐)-1H-이미다졸-2-메탄올,145)1-부틸-α-(4-클로로페닐)-α-메틸-1H-이미다졸-2-메탄올,146)α-(4-클로로페닐)-1-(3-디메틸아미노프로필)-α-메틸-1H-이미다졸-2-메탄올,147)α-부틸-1-도데실-α-(2,3,4-트리메톡시페닐)-1H-이미다졸-2-메탄올,148)1-벤질-α-부틸-α-(3-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,149)1-벤질-α-부틸-α-(3-트리플루오로메틸페닐)-1H-이미다졸-2-메탄올,150)1-(2-시아노에틸)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,151)1-(3-아미노프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,152)1-(3-카르복시프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,153)1-(3-하이드록시프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,154)1-(2-메톡시카르보닐에틸)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,155)1-(3-하이드록시프로필)-α-페닐-1H-이미다졸-2-메탄올,156)1-(3-하이드록시프로필)-α-(4-메틸페닐)-1H-이미다졸-2-메탄올,157)1-(3-하이드록시프로필)-α-(4-메톡시페닐)-1H-이미다졸-2-메탄올,158)1-(3-하이드록시프로필)-α-(3,4-디클로로페닐)-1H-이미다졸-2-메탄올,159)1-(2-메톡시카르보닐에틸)-α-페닐-1H-이미다졸-2-메탄올,160)1-(4-하이드록시부틸)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,161)1-(3-시아노프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,162)1-(3-칼르복시프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,163)1-(3-메톡시카르보닐프로필)-α-(4-클로로페닐)-1H-이미다졸-2-메탄올,164)1-부틸-α-페닐-1H-피라졸-5-메탄올,165)α-(4-클로로페닐)-1-메틸-1H-피라졸-5-메탄올,166)1-메틸-α-(3,4,5-트리메톡시페닐)-1H-피라졸-5-메탄올,167)1-부틸-α-(3,4-트리메톡시페닐)-1H-피라졸-2-메탄올,168)4-브로모-1-메틸-α-페닐-1H-피라졸-5-메탄올,169)α-(4-클로로페닐)-1-메틸-α-페닐-1H-피라졸-2-메탄올,170)1-부틸-α-(4-클로로페닐)-α-메틸-1H-피라졸-2-메탄올,171)1-메틸-α-메틸-α-페닐-1H-피라졸-2-메탄올,172)1-메틸-α-(3,4,5-트리메톡시페닐)-1H-피라졸-2-메탄올,173)1,3-디메틸-α-메틸-α-페닐-1H-피라졸-2-메탄올,174)α-에테닐-1-메틸-α-페닐-1H-피라졸-2-메탄올,175)1-부틸-α-(4-클로로페닐)-α-에테닐-1H-피라졸-2-메탄올,176)4-크로로-1-메틸-α-페닐-1H-피라졸-2-메탄올,177)4-메틸-α-(2-메틸페닐)-1H-피라졸-2-메탄올,178)1-메틸-α-(클로로페닐)-1H-피라졸-2-메탄올,179)1-메틸-α-(4-메틸페닐)-1H-피라졸-5-메탄올 ,180)1-메틸-α-(2-클로로페닐)-1H-피라졸-5-메탄올181)1-메틸-α-(4-메톡시페닐)-1H-피라졸-5-메탄올182)α-(4-클로로페닐)-α-메틸-0-(2-트리메틸암모니프로필)-1H-이미다졸-2-메탄올 요오드,183)α-(4-클로로페닐)-α-메틸-0-(3-트리메틸암모니프로필)-1H-이미다졸-2-메탄올 요오드,184)α-(4-메톡시페닐)-α-메틸-1-0-(2-트리메틸암모니프로필)-1H-이미다졸-2-메탄올 요오드,185)α-(4-클로로페닐)-α-메틸-0-(3-트리메틸암모니프로필)-1H-이미다졸-2-메탄올 요오드,186)α-(4-메톡시페닐)-α-메틸-1,1-디메틸이미다졸리오-2-메탄올 요오드.
- 다음의 일반식(II)로 표시되는 화합물을 다음의 일반식(III)으로 표시되는 화합물과 반응시켜서 제1항의 일반식(I)로 표시되는 아릴헤테로아릴카르비놀 유도체를 제조하는 방법.여기서,R1내지R4,R6,R7및 Het는 제1항에서 언급한 바와 같고,X는 할로겐 원자나 토실옥시 및 메실옥시 중에서 선택된 이탈기를 나타낸다.
- 제3항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 환원시켜서 제조됨을 특징으로 하는 방법.여기서,R1,R2,R3및 Het는 제1항에서 언급한 바와 같다.
- 제3항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 다음 일반식(나)로 표시되는 그리나드시약과 반응시켜서 제조됨을특징으로하는 방법.여기서,R1,R2,R3,R4및 Het는 상기와 같고, X는 할로겐 원자를 나타낸다.
- 제3항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 알데히드를 Het-Li형 화합물과 반응시켜서 제조됨을특징으로하는 방법.여기서,R1,R2,R3,및 Het는 상기와 같으며, Li는 리튬 원자를 나타낸다.
- 일반식(II)로 표시되는 화합물을 다음 일반식(IV) 표시되는 화합물과 반응시켜서 제1항의 일반식(I)로 표시되는 아릴헤테로아릴카르비놀 유도체를 제조하는 방법.여기서,R1내지R4,R6,R7및 Het는 제1항에서 언급한 바와 같고, X는 할로겐원자나 토실옥시 및 메실옥시 중에서 선택된 이탈기를 나타낸다.
- 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 환원시켜서 제조됨을 특징으로 하는 방법.여기서,R1,R2,R3,및 Het는 상기와 같다.
- 제7항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 다음 일반식(나)로 표시되는 그리나드시약과 반응시켜서 제조됨을 특징으로 하는 방법.여기서,R1,R2,R3R4,및 Het는 상기와 같고,X는 할로겐 원자를 나타낸다.
- 제7항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(VI)로 표시되는 알데히드를 Het-Li형 화합물과 반응시켜서 제조됨을 특징으로 하는 방법.여기서,R1,R2,R3,및 Het는 상기와 같으며, Li는 리튬원자를 나타낸다.
- 다음 일반식(II)로 표시되는 화합물은 다음 일반식(가)로 표시되는 화합물과 반응시켜서 제1항일반식(I)로 표시되는 아릴헤테로아릴카르비놀 유도체를 제조하는 방법.여기서,R1내지 R4,R8및 Het는 제1항에서 언급한 바와 같고,n은 1또는 2이다.
- 제11항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 환원시켜서 제조됨을 특징으로 하는 방법.여기서,R1, R2,R3,R4및 Het는 상기와 같다.
- 제11항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(V)로 표시되는 화합물을 다음 일반식(나)로 표시되는 그리나드시약과 반응시켜서 제조됨을 특징으로 하는 방법.여기서,R1, R2,R3및 Het는 상기와 같고,X는 할로겐 원자를 나타낸다.
- 제11항에 있어서, 일반식(II)로 표시되는 화합물은 다음 일반식(VI)로 표시되는 알데히드를 Het-Li형 화합물과 반응시켜서 제조됨을 특징으로 하는 방법.여기서,R1, R2,R3및 Li는 리튬원자를 나타낸다.
- 다음의 일반식(I)로 표시되는 화합물에서 Het가 피라졸을 나타내는 다음 일반식(Ⅶ)로 표시되는 화합물은그의 전구체 화합물을 직접 할로겐화시켜서 제조되어짐을 특징으로 하는 방법여기서,R1내지 R5및 Het는 제1항에서 언급한 바와 같고, R10은 수소원자나,브롬이나 염소와 같은 할로겐원자를 나타낸다.
- 다음의 일반식(I)로 표시되는 화합물을 요오드화메틸과 반응시켜서 다음의 일반식(Ⅷ)로 표시되는 화합물을 제조하는 방법.여기서,R1내지 R5,R6,R7및 Het제1항에서 언급한 바와 같다.
- 다음의 일반식(X)로 표시되는 화합물을 요오드화메틸과 반응시켜서 다음의 일반식(IX)로 표시되는 화합물을 제조하는 방법.여기서,R1내지 R5및 R11제1항에서 언급한 바와 같다.
- 제1항의 일반식(I)로 표시되는 유도체와 그의 치료학적으로 허용가능한 염으로 제조된 통증치료용약제.
- 약제학적으로 허용가능한 부형제외에 제1항의 일반식(I)로 표시되는 유도체중 적어도 하나 또는 그의 생리적으로 허용가능한 염중 적어도 하나를 함유시켜서된 약제조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8705118A FR2613720B1 (fr) | 1987-04-10 | 1987-04-10 | Derives d'aryl-heteroaryl carbinols avec activite analgesique |
FR8705118 | 1987-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880012558A true KR880012558A (ko) | 1988-11-28 |
KR930009442B1 KR930009442B1 (ko) | 1993-10-04 |
Family
ID=9350010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880004094A KR930009442B1 (ko) | 1987-04-10 | 1988-04-11 | 진통활성을 갖는 아릴헤테로아릴카르비놀 유도체와 그의 제조방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5017596A (ko) |
EP (1) | EP0289380B1 (ko) |
JP (1) | JPH0651678B2 (ko) |
KR (1) | KR930009442B1 (ko) |
AT (1) | ATE116303T1 (ko) |
BR (1) | BR1100931A (ko) |
DE (1) | DE3852565T2 (ko) |
DK (1) | DK172927B1 (ko) |
ES (1) | ES2014523A6 (ko) |
FR (1) | FR2613720B1 (ko) |
GR (1) | GR3015616T3 (ko) |
PT (1) | PT87183B (ko) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2681322B1 (fr) * | 1991-09-12 | 1993-12-17 | Laboratorios Dr Esteve Sa | Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments . |
WO1995029898A1 (en) * | 1994-05-02 | 1995-11-09 | Zeneca Limited | Herbicidal hydroxybenzyl-substituted heteroaryl compounds and derivatives thereof |
ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
ES2137136B1 (es) * | 1998-05-18 | 2000-07-01 | Esteve Labor Dr | Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica. |
ES2150378B1 (es) | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
DE10335566A1 (de) * | 2003-07-31 | 2005-02-24 | Grünenthal GmbH | Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
ES2245226B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
JP2007531785A (ja) * | 2004-04-05 | 2007-11-08 | ラボラトリオス・デル・デエレ・エステベ・エセ・ア | 活性物質組合せ物 |
EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
US20060040924A1 (en) * | 2004-06-22 | 2006-02-23 | Laboratorios Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic |
EP1632227A1 (en) * | 2004-09-07 | 2006-03-08 | Laboratorios del Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
EP1671968A1 (en) | 2004-12-17 | 2006-06-21 | Laboratorios Del Dr. Esteve, S.A. | Process for obtaining enantiomers of thienylazolylalcoxyethanamines |
EP1671953A1 (en) | 2004-12-17 | 2006-06-21 | Laboratorios Del Dr. Esteve, S.A. | Process for obtaining cizolirtine and its enantiomers |
EP1674465A1 (en) | 2004-12-27 | 2006-06-28 | Laboratorios Del Dr. Esteve, S.A. | Process for obtaining enantiomers of thienylazolylalcoxyethanamines |
WO2006087147A2 (en) * | 2005-02-15 | 2006-08-24 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
EP1690537A1 (en) * | 2005-02-15 | 2006-08-16 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia |
EP1695704A1 (en) * | 2005-02-28 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
ES2286920B1 (es) * | 2005-02-15 | 2008-08-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia. |
EP1743890A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
EP1743892A1 (en) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1757587A1 (en) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
US7592362B2 (en) * | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
EP2151234A1 (en) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion |
US20100291151A1 (en) * | 2009-04-21 | 2010-11-18 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL39413A0 (en) * | 1971-05-13 | 1972-07-26 | Sparamedica Ag | Benzodiazepine derivatives,their preparation and pharmaceutical compositions containing them |
BE793407A (fr) * | 1971-12-28 | 1973-06-28 | Hoechst Ag | Imidazolyl - (2) -carbinols ayant une activite hypolipidemique et leur procede de preparation |
JPS5118950B2 (ko) * | 1972-06-30 | 1976-06-14 | ||
US4853404A (en) * | 1986-10-13 | 1989-08-01 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives composition and use |
-
1987
- 1987-04-10 FR FR8705118A patent/FR2613720B1/fr not_active Expired - Lifetime
-
1988
- 1988-03-28 DK DK198801701A patent/DK172927B1/da not_active IP Right Cessation
- 1988-03-30 ES ES8800984A patent/ES2014523A6/es not_active Expired - Fee Related
- 1988-04-06 DE DE3852565T patent/DE3852565T2/de not_active Expired - Lifetime
- 1988-04-06 AT AT88400828T patent/ATE116303T1/de not_active IP Right Cessation
- 1988-04-06 EP EP88400828A patent/EP0289380B1/fr not_active Expired - Lifetime
- 1988-04-07 PT PT87183A patent/PT87183B/pt not_active IP Right Cessation
- 1988-04-08 JP JP63088020A patent/JPH0651678B2/ja not_active Expired - Lifetime
- 1988-04-11 KR KR1019880004094A patent/KR930009442B1/ko not_active IP Right Cessation
-
1989
- 1989-12-21 US US07/456,077 patent/US5017596A/en not_active Expired - Lifetime
-
1995
- 1995-03-23 GR GR950400692T patent/GR3015616T3/el unknown
-
1997
- 1997-05-14 BR BR1100931-4A patent/BR1100931A/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP0289380A1 (fr) | 1988-11-02 |
DK170188D0 (da) | 1988-03-28 |
EP0289380B1 (fr) | 1994-12-28 |
US5017596A (en) | 1991-05-21 |
BR1100931A (pt) | 1999-11-23 |
GR3015616T3 (en) | 1995-06-30 |
JPS63267761A (ja) | 1988-11-04 |
DK172927B1 (da) | 1999-10-04 |
ATE116303T1 (de) | 1995-01-15 |
JPH0651678B2 (ja) | 1994-07-06 |
FR2613720A1 (fr) | 1988-10-14 |
DE3852565D1 (de) | 1995-02-09 |
PT87183A (pt) | 1988-05-01 |
DE3852565T2 (de) | 1995-05-11 |
FR2613720B1 (fr) | 1990-01-19 |
KR930009442B1 (ko) | 1993-10-04 |
ES2014523A6 (es) | 1990-07-16 |
PT87183B (pt) | 1992-08-31 |
DK170188A (da) | 1988-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880012558A (ko) | 진통활성을 갖는 아릴헤테로아릴 카르비놀 유도체와 그의 제조방법 | |
KR900003154A (ko) | 우울증 치료제인 n-치환된 니코틴아미드 화합물 | |
DE3750596D1 (de) | 1,2,3,3a,8,8a-Hexahydro-1,3a,8-Trimethylpyrrolo[2,3-b]indole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel. | |
KR860001807A (ko) | 진통제 1,2-벤즈이소티아졸-3-일 피페라진 유도체 | |
UA41254C2 (uk) | ПОХІДНЕ ТЕТРАГІДРОКАРБАЗОЛУ АБО ЙОГО СІЛЬ, СОЛЬВАТ АБО ГІДРАТ ЯК АГОНІСТ 5-НТ<sub>1</sub>-ПОДІБНОГО РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ | |
HUP9900949A2 (hu) | Triazolilcsoportot tartalmazó foszfátok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
NO165070C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydrobenztiazoler. | |
RU2006111582A (ru) | Производные 1-бензоилпиперазина в качестве ингибиторов поглощения глицерина для лечения психозов | |
NZ272357A (en) | Use of various pyrazole or pyrimidino(or pyrazole or pyrimidinopyrrole derivatives for preparing medicaments for treatment of psychiatric disorders | |
KR960701878A (ko) | 수용성 캄프토테신 유도체, 이의 제조 방법 및 항종양제로서의 이의 용도(Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents) | |
RU2005120770A (ru) | Производные индазола, как антагонисты крф | |
DE3670081D1 (de) | Imidazolderivate, verfahren zu deren herstellung, deren anwendung und pharmazeutische zusammenstellungen. | |
KR890003730A (ko) | 1-페닐-3-(1-피페라지닐)-1h-인다졸, 그의 제조방법 및 중간생성물, 및 약제로서의 용도 | |
DE69021823D1 (de) | 3-Aryl-Oxazolidinone, Verfahren zu ihrer Herstellung und ihre Anwendung in der Therapie. | |
BG41124A3 (en) | Method for preparing benzamides | |
KR900006330A (ko) | 피롤로[3,2-e]피라졸로[1,5-a]피리미딘 유도체 및 이를 함유하는 약제 | |
KR890000481A (ko) | 트리사이클릭 피리돈 유도체 | |
ES2131574T3 (es) | Derivados de 1-(arilalquil-aminoalquil)imidazol, procedimientos de preparacion y uso como agentes terapeuticos. | |
KR890014542A (ko) | 4-치환된 피라졸로[3,4-d] 피리미딘 유도체 | |
KR870003098A (ko) | 치환된 3-(4-페닐-1-피페라지닐)알킬퀴나졸린-2,4-(1h,3h)디온의 제조방법 | |
PT82175A (de) | Neue 3-pyridylmethylnaphthylderivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
AR009556A1 (es) | Compuestos derivados de indazol triciclico, procedimiento de preparacion del mismo; medicamento y composicion farmaceutica que lo contienen | |
ATE42291T1 (de) | Spiro(indolo(1,7-ab>(1,5>benzodiazepin-2,4'piperidine> und zwischenprodukte, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel. | |
NO166179C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive aralkyl -4h-1,2,4-triazolderivater. | |
MXPA97009393A (es) | Uso de derivados de fenoxipiridina para el tratamiento de enfermedades causadas por trastornos delsistema dopamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20060926 Year of fee payment: 14 |
|
LAPS | Lapse due to unpaid annual fee |